Anavex Life Sciences Corp (AVXL)

[sokol]

Investor: You raise good points. Yes, if Anavex proves in its placebo controlled AD trial that AVXL 2-73 reduces amyloid plaque alone, Anavex has likely hit a home run as far as AD is concerned. It is, however, more significant if Anavex proves 2-73 also reduces tau. In addition, the current Anavex AD trial is a good chance for advancement or progress in gaining the FDA's acceptance of other biomarkers involved in Anavex’s clinical trials. Acceptance by the FDA of other biomarkers may then be utilized in future trials for other CNS indications.